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Abstract
Hepatocellular carcinoma (HCC) is a type of primary liver cancer that is responsible for
roughly 700,000 deaths around the world each year. While invasive treatment methods for HCC
have proven to be limited, there are drug treatments available that show promising features. The
structural elements of these drugs have given rise to an interest in guaipyridine alkaloids,
specifically a family of naturally occurring guaipyridine alkaloids known as the rupestines. The
rupestines have previously been isolated from the flowers of the plant Artemisia rupestris. This
plant has been known for its reported antitumor, antiviral and antibacterial properties when used
in traditional Chinese medicine. An additional guaipyridine alkaloid worth noting is cananodine,
which has been isolated from the fruits of Canaga odorata. Cananodine has shown activity toward
two lines of HCC cancer cells, with potency greater than the HCC drug treatment Sorafenib. This
increase in bioactivity has made the core guaipyridine structure of cananodine an attractive
synthetic target. Considering the rupestines contain this same bicyclic core, it is possible that they
will reveal similar activity to that of cananodine. In this report, rupestines B-D and J-M are targeted
for total synthesis. The synthesis of rupestine D has been reported in 6 steps from a picolyl bromide
substrate in good to excellent step-wise yields. The formation of the 7-membered carbocycle to
establish the key guaipyridine core is accomplished via an intramolecular Mizoroki-Heck
cyclization. This forms in a mixture of rupestine D and epi-rupestine D in a 1:2 ratio. Isolation of
rupestine D has proven to be difficult when using the initial synthetic route. Upon reversal of the
final two synthetic steps, the separation of diastereomers was accomplished with ease, allowing
for the synthesis of rupestine D as a single diastereomer. These methods were employed for the
synthesis and isolation of rupestine C in 6 steps with poor to excellent step-wise yields. The methyl
ketone-containing rupestine D and epi-rupestine D can then serve as the starting material for the
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syntheses of rupestines J and K, as well as L and M. Rupestine K has been synthesized and isolated
via a Rubottom oxidation of a silyl enol ether substrate. Progress is currently being made toward
the synthesis of rupestine J, L and M.
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Introduction
1.1 Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the most common form of liver cancer that results in
approximately 700,000 deaths around the world each year.1 HCC has been reported to be the third
most common cause of cancer-related death worldwide with diagnosis tripling in the last 40
years.1,2 HCC cases are most prevalent in Sub-Saharan Africa and Southeast Asia, where hepatitis
B and aflatoxin exposure are common.1 Underlying liver diseases such has hepatitis B (HBV),
hepatitis C (HCV) and cirrhosis of the liver are seen in a majority of HCC patients. 3,4 Cirrhosis is
scarring of the liver tissue that prevents the cells from being functional again. This is most often
seen in HBV and HCV patients, but is also seen in cases of chronic alcohol use.5
Recently, progress has been being made toward the treatment of HCV related HCC with directacting antiviral (DAA) agents. It was found the HCV related HCC patients had a 61.4% chance at
a 5-year overall survival (OS, survival time after diagnosis) when using DAA agents, and a 24.2%
chance of a 5-year OS without DAA agents.6 Liver function can also decrease as a result of
metastasis, where the cancer grows secondary tumors external to the primary tumor. The rate at
which the liver loses its function after the time of diagnosis plays a crucial role in the ability to
treat HCC. It was reported that 44% of patients diagnosed with HCC prior to loss in liver function
have a 33% chance of a 5-year OS.7 The chance of a 5-year OS decreases to 11% once the cancer
has metastasized and 2% once the cancer has spread to another region in the body.7 Significant
progress has been made when it comes to potential treatments for HCC, however invasive methods
including chemotherapy, radiation, and surgical resection have shown limited effectiveness. It has
previously been reported that only 10-15% of cases show responses to chemotherapy and radiation,
and less than 18% of patients are candidates for surgical resection.8 While these invasive methods

can be beneficial for a number of patients, it is crucial to continue investigating treatments that can
impact a greater fraction of HCC patients.8

1.2 HCC treatment methods
A kinase is an enzyme that is responsible for phosphorylation of certain biomolecules.
Small molecule kinase inhibitors are an attractive class of drugs because of their potential ability
to treat cancer.9 Kinase inhibitors function as competitors with adenosine triphosphate (ATP).
When the binding of a kinase inhibitor is favored over the binding of ATP, phosphorylation of
target proteins cannot occur.10 Type I kinase inhibitors prevent phosphorylation by binding to the
active site of the target enzyme, while type II kinase inhibitors will bind to the active site in a way
that alters the conformation of the enzyme, forcing it into an inactive form. 9 In order to design
effective type II kinase inhibitors, it is necessary to have an understanding of the SARs (structure
activity relationships) that occur at the enzymes active site.
There are currently 37 FDA-approved kinase inhibitors that can be divided into groups
based on their target kinases.10 For HCC treatment, the active site residues responsible for tumor
progression are serine and threonine kinases (Raf-1 and B-Raf).11 Inhibition of these protein
kinases has been achieved with a drug known as sorafenib (Nexavar® [1.1]) which was approved
by the FDA in 2007 for HCC treatment.11 While the average survival rate is increased by 2.8
months when taking sorafenib, the cost of treatment falls around $15,000 per month.12 A derivative
of sorafenib known as regorafenib (Stivarga®, [1.2]) was approved by the FDA in 2017 for the
treatment of HCC.13 This derivative has been shown to have similar effectiveness to that of
sorafenib, with a survival increase of 2.8 months compared to the placebo group.13 The only
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structural difference between 1.1 and 1.2 is the presence of a fluorine atom adjacent to the aryl
urea in 1.2.

Sorafenib has shown activity toward the Hep G2 cell line of HCC, with a potency (IC50
value) of 4.5 M.11 This results in the inhibition of the B-Raf and C-Raf protein kinases.11 In order
to understand how this inhibition process occurs, it is necessary to consider the functional groups
present in both the drug and the active site residues. This interaction can be seen in 1.3 (Figure 1),
where the pyridine head group of sorafenib (or regorafenib) interacts via hydrogen-bonding with
the cystine 531 residue of the B-Raf kinase. As the drug approaches this active site, the inactive
conformation of the B-Raf kinase is induced, preventing any further tumor growth. These
hydrogen-bonding capabilities have made pyridine moieties a common feature among type II
kinase inhibitors.14 It should also be noted that the diaryl urea group present in sorafenib and
regorafenib is a common functional group in type-II kinase inhibitors (interactions with other
residues not shown).

Figure 1. Hydrogen-bonding interactions between the cysteine 531 residue of the B-Raf kinase
and HCC drug treatments sorafenib and regorafenib.
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Similar derivations of these key structural features have recently been synthesized and
utilized for HCC treatment. In 2018, the FDA approved lenvatinib (Lenvima® [1.4]) as an
additional first line treatment.15,16 It was found that lenvatinib was not statistically superior to
sorafenib, however, it has become the new first line treatment because of its increase in
progression-free survival.17 In 2019 the FDA approved cabozantinib (Cabometyx® [1.5]) as a
second line treatment for patients with little to no response to first line therapies.17,18

1.3 Natural Products: Cananodine and Rupestines
Natural products play a crucial role in drug development and cancer treatment. A naturally
occurring guaipyridine alkaloid known as cananodine was isolated from the fruits of Cananga
odorata (trivially known as the “ylang-ylang” tree).19 Upon distillation of the ylang-ylang tree
flowers, an essential oil is obtained and used in perfumes and for aromatherapy.20 This plant
belongs to the Annonaceae family which is known for treating malignant tumors.21 C. odorata has
been used in Taiwanese folk medicine, specifically for the topical treatment of asthma and malaria,
and the oral treatment of stomach ulcers and fevers.22 The discovery of cananodine began when
Wu et al. successfully isolated eight different compounds from the fruits of C. odorata, a
guaipyridine alkaloid, cananodine (1.6), three eudesmane sesquiterpenes, cryptomerediol 11--L-
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rhamnoside (1.7), -eudesmol 11--L-rhamnoside (1.8) and -eudesmol (1.9) and four alkaloids,
(+)-ushinsunine--N-oxide (1.10), cleistopholine (1.11), N-trans-feruloyltyramine (1.12) and
lyscamine (1.13).22 Guaipyridine alkaloids like cananodine are attractive target compounds
because they possess a unique structure consisting of a seven-membered carbocycle that is fused
to a pyridine ring. Recall that the type II kinase inhibitors previously mentioned also contain this
pyridine head group, making the family of guaipyridine alkaloids a promising group for potential
HCC treatment.

Figure 2. Natural products isolated from the fruits of Cananga odorata.

Cananodine was found to be biologically active, possessing activity toward two different cell
lines in HCC.22 An IC50 value of 0.94 M was shown toward the Hep G2 cell line of HCC, which
corresponds to a greater potency than the previously mentioned type II kinase inhibitors.22 An IC50
value of 3.8 g/mL was shown toward the Hep 2,2,15 cell line, which was not seen in the previous
drugs at all.22 These results suggest that cananodine could be a more effective drug than sorafenib
and regorafenib. The predicted binding sites of cananodine to the active site of the B-Raf kinase
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(1.14) are shown in Figure 3, where the pyridine nitrogen remains a hydrogen-bond acceptor, and
now a tertiary alcohol acts as the hydrogen bond donor (as opposed to the amide nitrogen of
sorafenib/regorafenib).

Figure 3. Proposed hydrogen-bonding interactions between the cysteine 531 residue of the BRaf kinase and cananodine.

These promising results seen with cananodine have made guaipyridine alkaloids an interesting
target for potential drug therapy. A group of guaipyridine alkaloids known as the rupestines (Figure
4) have previously been isolated from Artemisia rupestris. A. rupestris is a plant that has been used
in traditional Chinese medicine for its antiviral, antibacterial and antitumor properties.23 In 2010,
Asia et al. isolated rupestines A-D (1.15-1.18), followed by rupestines F-M (1.19-1.26) in 2012
(Figure 4).23 Each rupestine possesses the same bicyclic system that is present in cananodine. The
differences between each of these alkaloids are seen at the 5- and 8-positions where there is varying
stereochemistry. Additionally, the substituent at the 8-position varies, allowing a wide range of
potential bioactivity via hydrogen bond donating and accepting. Both cananodine and the
rupestines can only be isolated naturally in impractically small quantities, making them an
attractive synthetic target.
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Figure 4. Rupestines A-M

1.4 Previous Synthetic Studies: Guaipyridine Alkaloids
Before cananodine became a sought-after natural product, Büchi and van der Gen reported the
first syntheses of guaipyridine alkaloids. Büchi et al. accomplished the isolation of two naturally
occurring sesquiterpene alkaloids from patchouli oil, patchoulipyridine (1.27) and epiguaipyridine
(1.28).24 Upon investigation of these compounds by van der Gen et al., it was found that a major
component of patchouli oil, guaiol (1.29), revealed similar spectral properties to that of
epiguaipyridine.25 This was surprising considering guaiol (1.29) possesses 7R, 10S
stereochemistry, and Büchi reported epiguaipyridine as a 7R, 10R structure.
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Figure 5. Compounds synthesized and isolated by Büchi and van der Gen.

This led van der Gen to synthesize epiguaipyridine (1.28) and its C-10 epimer (1.30) from
substrates with already established configurations. Guaiol was subjected to a palladium catalyzed
alkene isomerization followed by ozonolysis to form the hydroxydiketone (1.31). Subsequent
treatment with hydroxylamine hydrochloride in boiling ethanol lead to the hydroxy pyridine
derivative (1.32). Upon dehydration with thionyl chloride, two alkene isomers were produced
(1.30 and 1.33). Spectral analysis revealed that the 10S epimer 1.30 was identical to the compound
isolated from patchouli oil and the compound isolated by Büchi et al. The synthesis of
epiguaipyridine (1.28) was accomplished from the sesquiterpene -gurjunene (1.34) via a diketone
intermediate similar to the synthesis of the C-10 epimer. The isolated epiguaipyridine revealed
spectral properties that differed from the C-10 epimer, proving that the configuration was initially
misassigned by Büchi. Two additional syntheses of 1.28 and 1.30 were later reported by Okatani
and Koyama et al.26 The first synthesis was accomplished via a Diels-Alder reaction of 1,2,3triazine with enamines which produced three isomeric products (1.28, 1.30 and 1.38) (Scheme 1).
The desired products, 1.28 and 1.30 were obtained in a 2:1 diastereomeric ratio. In the second
synthesis, 1.35 was treated with O-(-methylally)hydroxylamine to yield an oxime intermediate
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(1.39). Subsequent thermal decomposition provided compounds 1.28, 1.30, 1.40 and 1.41 (Scheme
2).
Scheme 1. Synthesis of epiguaipyridine and its C-10 epimer via a Diels Alder pathway.26a

Scheme 2. Synthesis of epiguaipyridine and its C-10 epimer via an oxime intermediate.26b

1.5 Previous Synthetic Studies: Cananodine
The first total synthesis of (+)-cananodine was reported by Craig and Henry in a total of 15
steps (Scheme 3).27 This provided the single stereoisomer (1.6) in 4% yield. In order to set the
stereochemistry, chiral auxiliaries were utilized. The desired auxiliary (1.42) was prepared in
multiple steps using (R)-(-)-citronellene and (S)-valinol-derived oxazolidinone. Moving forward,
the synthesis began with a diastereoselective allylation between the lithium enolate of the auxiliary
and bromide (1.43) to provide the desired 1,7-diene (1.44). To form the cycloheptene ring of
(1.46), a ring-closing olefin metathesis (RCM) was performed in the presence of the secondgeneration Grubbs catalyst. When attempting the subsequent desilylation in both acidic and basic
conditions, decomposition occurred. To alleviate this issue, the RCM step was switched with the
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desilylation to provide the deprotected intermediate (1.45). Both intermediates 1.44 and 1.45 were
able to be carried through the RCM in identical yields. After removal of the chiral auxiliary under
basic conditions, esterification of the primary alcohol (1.47) with 4-methyl-2-(4-tolylsulfonyl)-4pentenoic acid provided the desired alkene (1.48). This intermediate was then allowed to undergo
a decarboxylative Claisen rearrangement to provide the desired 1,6-diene (1.49). Microwaveirradiation was implemented, and the resulting product was a mixture of two of the four possible
diastereomers. In order to establish the pyridine ring of 1.50, ozonolysis of 1.49 was followed by
the addition of triphenylphosphine and ethanolic ammonia. The final step in the synthesis required
reaction of (1.50) with excess methyl magnesium bromide to yield the final product, (+)cananodine (1.6). This total synthesis provided promising results; however, due to the 4% over
yield, it would not be practical to apply on an industrial scale.

Scheme 3. Synthesis of (+)-cananodine reported by Craig and Henry.27
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This led to the more recent total synthesis of (+)-cananodine which was accomplished in
2017 by Shelton et al. (Scheme 4).28 The key step in this synthesis was an intramolecular epoxide
opening reaction to form the seven-membered carbocycle of the guaipyridine core. The synthesis
began with the pyridyl iodide substrate (1.51) undergoing a palladium catalyzed cross-coupling
reaction with dienylboronate (1.52) in the presence of silver oxide. The diene intermediate (1.53)
then underwent an asymmetric dihydroxylation to provide diol (1.54), which was converted to the
epoxide (1.55) via a mesylate intermediate. The epoxide was then subjected to n-butyllithium
which deprotonated the picolyl position of the pyridine ring and allowed for formation of the 7membered carbocycle of 1.56. The final step in the synthesis was a hydrogenation of the 1,1disubstituted alkene in the presence of Wilkinson’s catalyst to afford the desired (+)-cananodine
(1.6) and its epimer (1.57) in a 1:1 ratio. While these results were encouraging, a downfall in the
synthesis is seen in the step involving n-butyllithium. Since there are two possible sites of picolyl
proton abstraction, there is roughly a 50% chance that the desired proton will be removed to form
the cyclized product. Additionally, the non-diastereoselective hydrogenation led to an inseparable
mixture of diastereomers.
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Scheme 4. Synthesis of (+)-cananodine and its epimer by Shelton et al.28

Shelton et al. also reported the synthesis of ent-cananodine (1.60) starting from the same
pyridyl iodide substrate (1.51). The key differing step is seen in the dihydroxylation of 1.53 with
AD-mix  instead of the previously implemented AD-mix  (Scheme 5). The subsequent steps
were carried out similar to Scheme 4 and the resulting ent-cananodine (1.50) and its epimer (1.61)
were formed in a 1:1 ratio.

Scheme 5. Synthesis of ent-cananodine and its epimer by Shelton et al.28

12

The most recently reported synthesis of cananodine by Shelton et al. was accomplished via
an intramolecular Mizoroki-Heck cyclization (Scheme 6).29 The synthesis began with the
alkylation of picolyl bromide (1.62) with methyl 5-hexenoate using LHMDS. The allyl ether of
intermediate 1.63 was then removed using a palladium(0) catalyst in the presence of potassium
carbonate and methanol. After triflation of 1.64 with N-phenyltriflimide, 1.65 was reacted using
the optimal Heck cyclization conditions. After a simple hydrogenation with palladium on carbon,
the methyl ester diastereomers (1.67 and 1.68) were separated. Intermediate 1.68 was then exposed
to 3 equivalents of methyl lithium to provide cananodine in a 70% yield. Rupestine D (1.18) was
also obtained as a side product in a 9% yield.

Scheme 6. Synthesis of cananodine by Shelton et al.29
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1.6 Previous Synthetic Studies: Rupestines
As previously mentioned, isolating the rupestines naturally is not a practical method for
obtaining them for biological screening. This gave motivation for their syntheses, and lead to the
first synthesis of rupestine G in 2018 (Scheme 7).30 The synthesis began with oxidation of the
commercially available 5-bromo-2-picoline (1.70) to form the pyridine N-oxide (1.71). This was
followed by a modified Reissert-Henze reaction to form the 2-cyanopyridine (1.72) and a
decarboxylative Blaise reaction with potassium methyl malonate to provide 1.73. This
intermediate was alkylated with allyl bromide using sodium ethoxide as the base forming
intermediate 1.74. This set the stage for the Suzuki cross-coupling reaction which utilized
isopropenylboronic acid pinacol ester to form intermediate 1.75. This was followed by the key
ring closing metathesis reaction which was catalyzed by the Grubbs II catalyst. Once the 7membered carbocycle of 1.76 was formed, NMR analysis allowed for conclusion that the enol
form was favored over the ketone. Intermediate 1.76 was then treated with sodium borohydride in
methanol to afford the chiral alcohol (1.77). Dehydration of the alcohol with methanesulfonyl
chloride to form diene (1.78) was followed by a simple hydrogenation reaction to provide rupestine
G and its epimers (1.79) in an overall 18.9% yield.
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Scheme 7. Synthesis of rupestine G and its epimers by Yusuf et al.30

More recently, rupestines B and C have been synthesized by Starchman et al. (Scheme 8).31
This synthesis began with alkylation of picolyl bromide (1.62) with 3-oxopentanoate (1.80) to
form intermediate 1.81. This was followed by an additional alkylation with 4-iodo-1-butene to
provide the keto ester intermediate 1.82. The keto ester was then exposed to a palladium(0) catalyst
with potassium carbonate and methanol to cleave both allyl groups, leaving intermediate 1.83. In
order to form the precursor for the key intramolecular Heck cyclization, the phenol type alcohol
was converted to triflate 1.84. When this intermediate was subjected to palladium(0) catalyst in
basic dioxane at 130 C, the desired 7-membered carbocycle of 1.85 was formed. Finally, a simple
hydrogenation catalyzed by palladium on carbon lead to a 1:2 mixture of rupestines B (1.16) and
C (1.17) which are separable using reverse phase chromatography.
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Scheme 8. Synthesis of rupestines B and C reported by Starchman et al.31

Together, all of these previous syntheses provide a solid foundation for exploring the
syntheses of rupestines B-D and J-M. Specifically, the synthesis pathways reported by Shelton et
al. and Starchman et al. will be carried out for the synthesis of rupestine D. The major difference
in these syntheses is seen at the alkylation of picolyl bromide step. This will be adapted to better
suit the desired rupestine D product, and can be further modified to provide an additional route
toward rupestines B and C. Once the ketone-containing rupestines have been isolated, they can
serve as the starting material for the syntheses of rupestines J-M. To obtain rupestines J and K, a
Rubottom oxidation pathway will be used, and to obtain rupestines L and M, a Baeyer-Villiger
oxidation pathway will be used. These strategies will be utilized in hopes of isolating the rupestines
for bioactivity screening against HCC.
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2.0 Synthesis of Rupestine D
2.1 Initial Synthetic Route
Using an adaptation of the pathway established by Shelton et al., the first retrosynthetic
route was designed (Scheme 9). To establish the methyl ketone diastereomers (1.18 and 2.0), a
simple hydrogenation and Grignard reaction could be utilized. The guaipyridine core could then
be accessed through an intramolecular Heck cyclization of triflate 2.3. Finally, the triflate
intermediate would be formed via alkylation of 5-hexenenitrile (2.5) and picolyl bromide (1.62).

Scheme 9. Proposed retrosynthesis of rupestine D (1.18)

Using this desired pathway, the synthesis began with the alkylation of 1.62 and 2.5 in the
presence of LHMDS to provide intermediate 2.6 in a 77% yield after purification via flash
chromatography (Scheme 10). Cleavage of the allyl ether protecting group of 2.6 was
accomplished with a palladium(0) catalyst and K2CO3 in methanol to provide the phenol-type
intermediate (2.7) in an 82% yield. The crude mixture containing 2.7 was pure enough to move
forward without purification and was immediately reacted with N-phenyltriflimide in the presence
of triethylamine. This provided the Heck cyclization precursor (2.3) in a 94% yield after
purification via flash chromatography.
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Scheme 10. Synthesis of the Heck cyclization precursor (2.3) from 5-hexenenitrile (2.5) and
picolyl bromide (1.62).

2.2 Optimization of Intramolecular Mizoroki-Heck Cyclization
The Mizoroki-Heck reaction is a coupling reaction between a vinyl or aryl halide and an
alkene with the standard conditions being a base and palladium catalyst. While Richard F. Heck
was awarded a 2010 Nobel Prize in Chemistry for this transformation, in 1971 Mizoroki et al. was
the first to accomplish a palladium catalyzed reaction between alkenes and aryl iodides.32 Heck et
al. expanded on this report by incorporating benzyl and styryl halides as well as broadening the
scope of successful palladium catalysts and bases.33 The first intramolecular Heck cyclization for
the formation of oxindole derivatives was reported by Heck et al. in 1979.34 A decade later this
work was expanded on by Shibasaki et al. to access cis-Decalin via an asymmetric Heck-type
synthesis.35 More recently, in 2003 Overman revealed the use of this transformation for natural
product synthesis.36 This lead to Starchman et al. reporting a successful Mizoroki-Heck reaction
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between a terminal mono-substituted alkene and an aryl triflate using a palladium(0) catalyst that
allows access to the desired guaipyridine core of the rupestines.31
The investigation of the Mizoroki-Heck reaction on aryl triflate 2.3 began with Pd(PPh3)4
catalyst and K2CO3 in acetonitrile at 100 °C. Unfortunately, no cyclized material was formed, and
the NMR spectrum revealed pyridyl alcohol (2.7). Similar results were obtained when Pd(OAc)2
was utilized, the only difference being that reaction to pyridyl alcohol progressed much more
slowly (Entry 2). Moving forward with the Pd(PPh3)4 catalyst, a solvent investigation was done. It
was concluded that DMF and acetonitrile were not suitable for the transformation when unwanted
pyridyl alcohol 2.7 was formed. Finally, a temperature increase was made, resulting in the need
for new solvents, toluene and dioxane. In toluene, the starting pyridyl triflate was never fully
consumed and so the conditions were deemed impractical. In dioxane however, desired cyclized
product was obtained after one day. After purification, it was concluded that the cyclized material
was obtained in a 72% yield. Making entry 5 the most optimal set of conditions moving forward.

Table 1. Optimization of intramolecular Heck reaction

Entry

Catalyst

Base

Solvent

1
2
3
4
5

Pd(PPh3)4
Pd(OAc)2
Pd(PPh3)4
Pd(PPh3)4
Pd(PPh3)4

K2CO3
K2CO3
K2CO3
K2CO3
K2CO3

CH3CN
CH3CN
DMF
Toluene
Dioxane
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Temp
(°C)
100
100
100
130
130

Reaction
Time (days)
7
>14
1
>14
1

Yield (%)
0
0
0
72

The standard mechanism for the Mizoroki-Heck cyclization of triflate 2.3 is shown in
Scheme 11. Upon loss of two triphenylphosphine ligands, the palladium catalyst undergoes an
oxidative addition, inserting itself between the pyridine ring and the triflate group. An additional
ligand is then lost to allow for coordination with the monosubstituted alkene, forming the desired
seven-membered carbocycle. A -hydride elimination then occurs to reestablish the alkene,
relieving the desired product 2.2. The final step requires a base to re-generate the palladium
catalyst.
Scheme 11. Mizoroki-Heck reaction mechanism.
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2.3 Optimization of Grignard reaction
The next step in the synthesis required conversion of the nitrile (2.2) to the methyl ketone
of rupestine D. This was accomplished with methyl magnesium iodide in benzene. It should be
noted that the reaction was not successful in THF due to solvent interactions with the nitrile.37
These unfavorable solvent interactions were discussed in a 1980 report by Canonne et al. where
benzene was shown to be the superior solvent in Grignard reactions of nitriles specifically.

Scheme 12. Proposed equilibrium between the free nitrile and the magnesium coordinated nitrile
in the presence of benzene solvent.

Scheme 13. Proposed equilibrium between the free nitrile and the magnesium coordinated nitrile
in the presence of THF solvent.

After isolation of methyl ketone 2.1 in an 80% yield, the final step in the synthesis was a
simple hydrogenation with palladium on carbon to provide rupestine D (1.18) and epi-rupestine D
(2.0) in a 92% yield as a 1:2 ratio of diastereomers. Unfortunately, after multiple attempts it was
concluded that the diastereomers were inseparable and rupestine D could not be isolated.
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Scheme 14. Synthesis of rupestine D (1.18) and epi-rupestine D (2.0) from triflate (2.3).

2.4 Alternative Synthetic Route
In the initial synthesis of rupestine D, the second and final stereocenter was formed in the
last step of the synthesis. When the simple hydrogenation was performed in the presence of the
nitrile instead of the ketone, the diastereomers were obtained in a 95% yield as a 10:1 ratio of 2.9
to 2.8. Interestingly, these diastereomers were completely separable and allowed for isolation of
the rupestine D precursor (2.8) in a 15% yield which was carried through to rupestine D (1.18) in
a 93% yield. The epi-rupestine D precursor was obtained in a 58% yield and was carried through
to epi-rupestine D in a 55% yield. Not only did this alternative route allow for the isolation of
rupestine D, but it also provided a key step in the synthesis where diastereomers could be separated.
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Scheme 15. Alternative route toward isolation of rupestine D (1.18).

While the alternative route shown in Scheme 15 initially allowed for isolation of each
diastereomer, reproducibility of the transformation proved to be difficult. It was found that at room
temperature, there was a competing nucleophilic addition and deprotonation reaction occurring
and a 1.3:1 ratio of 2.0 to 1.18 was obtained. As the temperature of the reaction was decreased to
-78 °C, the desired nucleophilic addition was favored and only trace isomerization occurred.
Tables 2 and 3 compare 1H and 13C NMR data for the naturally isolated rupestine D and the one
synthesized in this experiment.
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Table 2. 1H NMR data comparison for rupestine D.23
Position

Natural Product

This work

H—C(3)
H—C(4)
H—C(5)
Ha—C(6)
Hb—C(6)
Ha—C(7)
Hb—C(7)
H—C(8)
Ha—C(9)
CH2(13) or Me(13)
Ha—C(14) or Me(14)
Me(15)

7.00 (d, J = 8.0)
7.40 (d, J = 8.0)
2.94 – 3.04 (m)
1.23 – 1.30 (m)
1.82 – 1.94 (m)
1.82 – 1.94 (m)
2.04 – 2.11 (m)
2.54 – 2.60 (m)
3.13 – 3.28 (m)
2.23 (s)
2.51 (s)
1.35 (d, J = 7.2)

7.37 (d, J = 8.2)
6.98 (d, J = 8.2)
2.90 – 3.04 (m)
1.20 – 1.35 (m)
1.75 – 2.00 (m)
1.75 – 2.00 (m)
2.00 – 2.15 (m)
2.54 (tt, J = 10.5, J = 3.0)
3.22 (dd, J = 14.1, J = 10.0)
2.22 (s)
2.50 (s)
1.34 (d, J = 7.2)

Table 3. 13C NMR data comparison for rupestine D.23
Position

Natural Product

This work

C(2)
C(3)
C(4)
C(5)
C(6)
C(7)
C(8)
C(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)

154.36
121.24
132.60
34.76
34.96
32.92
49.47
39.43
159.05
137.90
211.07
28.49
23.71
20.32

154.5
121.1
132.4
34.7
35.0
32.9
49.6
39.6
159.2
137.7
211.1
28.4
23.8
20.3
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2.5 Separation of Diastereomers
Many attempts were made to isolate rupestine D from its epimer via flash and radial
chromatography. Results were initially promising when a separation was run in a 1:1 hexanes:ethyl
acetate solvent system. As mentioned, the crude ratio of diastereomers 1.18 and 2.0 was 1:2, and
after separation, one fraction was obtained that contained a 1:6 ratio of diastereomers, and a second
fraction was obtained that contained a 1:2 ratio (Figure 6). This indicated that the isomers were at
least semi-separable. Numerous different solvent systems were tested via TLC before resulting to
an attempt at a reverse phase separation where a methanol:water solvent system was used. A
gradient was run over 15 minutes starting with 40% MeOH in H2O and ending in 85% MeOH in
H2O. Unfortunately, the diastereomers were still not isolated.

Figure 6. Separation of rupestine D and epi-rupestine D via radial chromatography (2mm, 1:1
hexanes:ethyl acetate).

When the hydrogenation was run in the presence of nitrile 2.2, radial chromatography was
an efficient method for separation (Figure 7). Directly upon 1H NMR analysis of the crude
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hydrogenated reaction, a 1:10 ratio of diastereomers 2.9 and 2.8 was obtained. After isolation of
each compound, 1:3.9 ratio was obtained (determined via percent yield). It is proposed that the
nitrile diastereomers are prone to isomerization on the slightly acidic silica gel of the radial
chromatotron plate.

2.9

2.8
Figure 7. Separation of nitriles 2.9 and 2.8 via radial chromatography (2mm, 1:3 hexanes:ethyl
acetate).

2.6 Hydrogenation: Diastereomeric ratios
The difference in the obtained diastereomeric ratios between ketone 2.1 and nitrile 2.2 upon
hydrogenation was puzzling. Hydrogenation of 2.1 provided a 2:1 ratio of the cis isomer to the
trans isomer, and hydrogenation of 2.2 lead to a 10:1 ratio of the cis to trans. Upon conformational
analysis, it is proposed that the most stable conformation of the alkene substrates holds the C8
functional group in a pseudo-equatorial position. As seen in figure 8, these conformations result
in the C7 and C9 pseudo-axial protons blocking the bottom face of the substrate, while the C8
pseudo-axial proton is blocking the top face. As the functional group at the C8 pseudo-equatorial
position gets larger, the C8 pseudo-axial proton gets closer to the 1,1-disubstituted alkene, making
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hydrogenation from the top face less favorable. This explains why the smaller nitrile-containing
alkene results in a higher percentage of the cis isomer compared to the larger methyl ketone.

Figure 8. Major conformation of alkenes 2.1 and 2.2.
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3.0 Synthesis of rupestines J and K
It was initially proposed that the alpha hydroxy alkene of rupestine J (1.23) could be
accessed through a Wittig reaction using epi-rupestine K (3.1) as the substrate. In order to form
the -hydroxy ketone of rupestine K (1.24) and to establish the C5 stereocenter, a benzoin
condensation followed by a simple hydrogenation would be utilized. Finally, the necessary
aldehyde substrate (3.3) could be accessed through a reduction of nitrile 2.2.

Scheme 16. Proposed retrosynthesis of rupestines J (1.23) and K (1.24).

3.1 Initial synthetic route
The synthesis of rupstines J and K began with the previously synthesized nitrile 2.2 from
the synthesis of rupestine D. This intermediate was reduced to aldehyde 3.3 in a 57% yield using
DIBAL-H followed by an acidic work up. It was then anticipated to perform a benzoin
condensation using an N-heterocyclic carbene catalyst, paraformaldehyde and triethylamine base.
This would ideally establish the desired alpha hydroxy ketone and would be followed by a
hydrogenation to form the final stereocenter. At this stage, separation of the diastereomers would
be necessary in order to isolate rupestine K (1.24) and carry epi-rupestine K (3.1) through a Wittig
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reaction to form rupestine J (1.23). Unfortunately, despite success in the literature, the synthesis
never made it past the benzoin condensation step.

Scheme 17. Initial synthetic studies toward rupestines J and K.

3.2 Benzoin Condensation
Benzoin condensations require the use of an N-Heterocyclic carbene (NHC) which are
known to be attractive organocatalysts for a number of transformations.38 The NHC catalyst
chosen for this synthesis was 3-ethylbenzothiazolium bromide which has been shown to be
successful in the microwave-assisted synthesis reported by Nikolaou et al.39 In order to preserve
the precious aldehyde substrate 3.3, a non-precious aldehyde substrate hexanal (3.4) was used for
reaction optimization. This was an especially attractive model substrate because Nikolaou et al.
had successfully achieved this transformation with heptanal.
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Table 4. Optimization of benzoin condensation on non-precious substrate 3.4.

Entry Catalyst Base
Base
Paraformaldehyde MW (Y/N) Conversion
(mol %)
(mol %)
(equiv)
(%)*
1
10
Et3N
20
3
N
25
2
10
Et3N
50
3
N
trace
3
10
Et3N
300
3
N
trace
4
10
DIPEA
20
3
N
7
5
10
DIPEA
20
3
Y
trace
*% conversion was determined via GCMS

The reaction investigation began with the relative molar equivalents established by
Nikolaou et al. (Table 4, Entry 1). GCMS did reveal product formation, however the reaction
profile was unfortunately complex and isolation was not accomplished. In attempt to increase the
percent conversion, the mol % of base was increased. It was proposed that since the end groups of
paraformaldehyde are alcohols, the base could be deprotonating the hydroxy group first. Entries 2
and 3 reveal that increasing the base mol % did not increase the percent conversion. Moving back
to the established molar equivalents reported by Nikolaou et al., DIPEA base was incorporated.
Without microwave radiation (entry 4), a 7% conversion was obtained. When microwave radiation
was employed (50 Watts, 100 °C), a trace conversion to the product was obtained.

3.3 Alternative synthetic route
A second approach to the synthesis of rupestines J and K was proposed (Scheme 18). The
final step toward rupestine J would remain the same as the initial synthesis (Scheme 16), where
excess Wittig reagent would allow for conversion of ketone 3.1 to alkene 1.23. In order to access
the alpha hydroxy ketone of rupestine K and its epimer, the methyl ketone of rupestine D would
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be converted to a silyl enol ether (3.6) and could be subsequently oxidized using a Rubottom
oxidation.

Scheme 18. Alternative proposed retrosynthesis of rupestines J and K.

Starting from a mixture of ketones 1.18 and 2.0, silyl enol ether 3.6 was formed in a
quantitative yield using 3 equivalents of LHMDS followed by 6-9 equivalents of TMSCl (Scheme
19). Purification of 3.6 via flash chromatography resulted in a significant amount of product
converting back to the substrate ketone. To avoid this, the silyl enol ether was not purified and was
instead carried straight through to the Rubottom oxidation.
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Scheme 19. Alternative synthesis of rupestines J and K.

3.4 Optimization of silyl enol ether formation
Initial studies for the transformation began with a slight excess of LDA followed by an
excess of TMS chloride. A small excess of base was used in anticipation of the picolyl methyl
group being deprotonated. Fortunately, since the reaction was kept at -78 °C, the undesired
deprotonation did not pose a problem. This allowed for a continuous increase in base equivalents
until the substrate was fully consumed.

Table 5. Optimization of silyl enol ether formation

Entry
Base
Base equiv.
1
LDA
1.1
2**
LHMDS
1.5
3**
LHMDS
2.1
4
LHMDS
3.1
*% conversions determined via GCMS
**substrate used was non-precious methyl undecyl ketone
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% conversion*
trace
50
92
100

3.5 Optimization of Rubottom Oxidation
The Rubottom oxidation is a reaction between trimethylsilyl enol ethers and mCPBA that
was first reported in 1974.40 This reaction was used more recently in 2008 for a scalable synthesis
of 2S-hydroxymutilin, making it a promising transformation for the synthesis of potentially
biologically active rupestines J and K.41 For the substrate in question (3.6) it is important to
consider the reaction between the pyridine nitrogen and mCPBA which results in an undesired
pyridine N-oxide. Upon the addition of mCPBA to a solution of the substrate, the most electron
rich functional group will react first. This means that with careful consideration of mCPBA
equivalents, the pyridine N-oxide can be avoided. Table 6 highlights the different ratios obtained
with varying equivalents of mCPBA. It was found that when 1.5 equivalents of mCPBA is
exceeded, the pyridine N-oxide begins to form and cannot be reduced back to the neutral pyridine.
However, when the mCPBA equivalents are less than or equal to 1.5, the starting enol ether
substrate is not fully consumed. Since the reaction work-up allows for conversion of any remaining
substrate 3.6 back to ketones 1.18 and 2.0, it was concluded that it was more practical to underoxidize 3.6 rather than over-oxidize. This leaves entry 2 as the optimal set of conditions. Upon
purification of a previous crude reaction batch, a pure fraction of rupestine K was isolated and
fully characterized. Tables 7 and 8 compare the 1H and 13C NMR obtained for the natural product
and this experiment.
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Table 6. Optimization of the Rubottom oxidation

Entry
mCPBA (equiv)
1
1.25
2
1.5
3
1.8
4
3
*Relative ratios were determined via GC-MS

S.M.:Product*
2:1
1:1
-

Product:N-Oxide*
2:1
1:1

Table 7. 1H NMR data comparison for rupestine K.23
Position

Natural Product

This work

H—C(3)
H—C(4)
H—C(5)
Ha—C(6)
Hb—C(6)
Ha—C(7)
Hb—C(7)
H—C(8)
Ha—C(9)
Hb—C(9)
Ha—C(13)
Me(15)
H—(16)

7.02 (d, J = 8.0)
7.41 (d, J = 8.0)
3.02 (m)
1.97 (m)
1.31 (m)
1.97 (m)
2.03 (m)
2.58 (m)
3.35 (dd, J = 14, J = 10.8)
3.12 (d, J = 14)
4.39 (s)
2.51 (s)
1.37 (d, J = 7.2)

7.00 (d, J = 7.9)
7.40 (d, J = 7.8)
3.00 (m)
1.97 (m)
1.30 (m)
1.97 (m)
2.02 (m)
2.56 (m)
3.32 (dd, J = 11.0, J = 14.0)
3.11 (d, J = 14.0)
4.37 (s)
2.49 (s)
1.36 (d, J = 7.0)
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Table 8. 13C NMR data comparison for rupestine K.23
Position

Natural Product

This work

C(2)
C(3)
C(4)
C(5)
C(6)
C(7)
C(8)
C(9)
C(10)
C(11)
C(12)
C(13)
C(15)
C(16)

154.2
121.5
132.6
34.8
34.8
33.3
45.2
39.5
159.3
137.7
208.9
66.8
23.6
20.4

154.7
121.4
132.7
34.8
34.8
33.3
45.2
39.5
158.5
137.7
212.0
66.8
23.8
20.3
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4.0 Synthesis of rupestines L and M
4.1 Intended synthetic route
Moving forward from the previously synthesized methyl ketone of rupestine D and epirupestine D, a new rupestine synthesis was proposed. The first step in the synthesis of rupestines
L and M was a Baeyer-Villiger oxidation (BVO) to form esters 4.0 and 4.1. This would be followed
by a hydrolysis step to form the desired hydroxyl diastereomers rupestine L (1.25) and rupestine
M (1.26) (Scheme 20). Should the hydroxyl diastereomers be inseparable, the syntheses of
rupestines L and M could ideally be started from the previously isolated nitriles (2.8 and 2.9).

Scheme 20. Proposed retrosynthesis of rupestines L and M.

4.2 Studies on Baeyer-Villiger oxidation
The studies for this synthesis began with the Baeyer-Villiger oxidation, where an oxygen
is inserted on the more substituted side of a ketone, forming the desired ester 4.0 (Scheme 21).
Initial attempts with the standard Baeyer-Villiger oxidant mCPBA were unsuccessful due to the
favorability of pyridine N-oxide formation (Scheme 22). The presence of the pyridine N-oxide was
confirmed via mass spectrometry and FTIR spectroscopy. Initially, the MS data was promising
when the M+ ion corresponded to a mass of 233.31 which is the mass of desired ester 4.0.
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However, the FTIR spectrum revealed a carbonyl C=O stretch around 1710 cm-1, indicating the
presence of a ketone.

Scheme 21. Proposed synthesis of rupestines L and M (1.25, 1.26).

Scheme 22. Formation of the undesired pyridine N-oxide.

Further attempts were made toward the formation of esters 4.0 and 4.1 with a new oxidant,
oxone. A Baeyer-Villiger oxidation with oxone in ionic solvents was reported by Chrobok et al.42
Unfortunately, the formation of the pyridine N-oxide was still occurring in presence of oxone.
After further literature searching, a new oxidant was found that has been used in Baeyer-Villiger
oxidations, boron trifluoride etherate with hydrogen peroxide.43 This reagent would not only
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provide an oxidant for the desired transformation, but ideally it would also allow the pyridine
nitrogen to complex with the boron trifluoride, inhibiting N-oxide formation (Scheme 23).

Scheme 23. Protection of the pyridine nitrogen with boron trifluoride.

Moving forward, a non-precious ketone substrate was utilized in order to conserve the
precious ketone substrates (1.18 and 2.0). Table 9 provides a summary of all attempted conditions.
After no desired product was obtained from entries 1 and 2, the standard BVO conditions were reemployed. It was determined that the temperature played an important role when the % conversion
increased as the temperature was increased. When the reaction was attempted in ether, no product
was obtained. It was concluded that the optimal conditions were mCPBA in DCM at 70 °C (entry
5).
Table 9. Optimization of Baeyer-Villiger oxidation with non-precious substrate 4.5.

Entry Oxidant
1
2
3
4
5
6

mCPBA
H2O2
mCPBA
mCPBA
mCPBA
mCPBA

Lewis Acid

Solvent

Temp (°C)

% Conversion*

BF3-etherate
BF3-etherate
-

ether
ether
DCM
DCM
DCM
ether

reflux
reflux
25
60
70
70

0
0
trace
~70
~90
0
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Unfortunately, when using the optimal conditions from Table 9 in the presence of the
precious ketone substrate mixture (1.18 and 2.0), only the pyridine N-oxide was recovered. Since
the formation of the pyridine N-oxide was inevitable, it was then proposed that it could be reduced
back to the neutral pyridine in a later step. A method for the removal of N-oxides with
triphenylphosphine was reported in 1959 by Howard et al.44 When the ketone substrates were
reacted in the presence of excess mCPBA at 70 °C for 3 days, only the pyridine N-oxide was
recovered. The temperature was then increased to 110 °C in benzene and 150 °C in dioxane and
no desired product was formed. It was finally concluded that the methyl ketone of 1.18 and 2.0 are
not reactive enough for this transformation and different routes will have to be explored.

Table 10. Optimization of Baeyer-Villiger oxidation with substrates 1.18 and 2.0.

Entry

Oxidant

Solvent

Temp (°C)

C=O IR stretch (cm-1)

1
2
3

mCPBA
mCPBA
mCPBA

DCM
benzene
DMF

70
110
150

1710
1709
1709
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5.0 Alternative synthesis to Starchman et al.’s synthesis of rupestines B and C
Ketone-containing guaipyridine alkaloids rupestines B and C differ from rupestine D and
epi-rupestine D by one methylene group. It was initially proposed that the ethyl ketone of
rupestines B and C could be accessed using the same initial synthesis of rupestine D and epirupestine D, with the exception of the methyl Grignard step. Instead, an ethyl Grignard would be
utilized to establish the ethyl ketone. This would be followed by a simple hydrogenation to form
the C5 stereocenter.

Scheme 24. Retrosynthesis of rupestines B and C from intermediate 2.2.

The intended path for the synthesis of rupestines B and C began with the previously
synthesized alkene nitrile 2.2. It was our hope that the ethyl ketone of 1.85 could be accessed
through an ethyl Grignard reaction (Scheme 24), however attempts were unsuccessful due to
reaction of the Grignard reagent and the 1,1-disubstituted alkene (Scheme 25).

Scheme 25. Undesired reaction with 1,1-disubstituted olefin of 2.2.
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This issue was alleviated when the alternative synthesis of rupestine D was employed,
where nitrile 2.9 was carried through to rupestine C in a 36% percent yield. Due to the fact that
reflux was required to accomplish this transformation, isomerization did occur, and a 55% yield
of a semi-separable mixture of rupestines B and C was obtained. Tables 11 and 12 reveal the 1H
and 13C data comparison for rupestine C between the natural product and this experiment.

Scheme 26. Desired reaction for the formation of rupestine C.

Table 11. 1H NMR data comparison for rupestine C (1.17).23
Position

Natural product (400 MHz)

This work (300 MHz)

H—C(3)
H—C(4)
H—C(5)
Ha—C(6)
Ha—C(7)
Hb—C(7)
H—C(8)
Ha—C(9)
Hb—C(9)
CH2(13) or Me(13)
Ha-C(14) or Me(14)
Me(15)
Me(16)

6.94 (d, J = 7.6)
7.33 (d, J = 7.6)
2.95 – 3.04 (m)
1.72 – 1.88 (m)
1.72 – 1.88 (m)
2.00 – 2.10 (m)
2.67 – 2.75 (m)
3.16 – 3.24 (m)
3.31 – 3.41 (m)
2.60 (q, J = 7.2)
1.02 (t, J = 7.2)
2.50 (s)
1.31 (d, J = 7.6)

6.92 (d, J = 7.7)
7.30 (d, J = 7.6)
2.94 – 3.04 (m)
1.73 – 1.89 (m)
1.73 – 1.89 (m)
1.97 – 2.10 (m)
2.65 – 2.72 (m)
3.17 (dd, J = 2.7, J = 14.7)
3.28 – 3.36 (m)
2.57 (q, J = 7.3)
1.02 (t, J = 7.3)
2.47 (s)
1.30 (d, J = 7.3)
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Table 12. 13C NMR data comparison for rupestine C (1.17).23
position
C(2)
C(3)
C(4)
C(5)
C(6)
C(7)
C(8)
C(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)
C(16)

Natural product (400 MHz)

This work (300 MHz)

154.63
121.42
136.59
37.65
32.11
28.40
48.50
39.57
157.63
138.14
213.38
34.29
7.76
23.56
18.85

154.67
121.25
136.26
37.70
32.18
28.28
48.66
39.97
157.75
137.84
213.56
34.26
7.78
23.85
18.79

42

6.0 Conclusions
In conclusion, the synthesis and isolation of rupestine D as a single diastereomer has been
reported in 6 total steps from picolyl bromide 1.62 in a 6.3% overall yield. The key step in the
synthesis was an intramolecular Mizoroki-Heck cyclization to form the desired bicycle
guaipyridine core. Upon the initial synthesis of rupestine D and epi-rupestine D, a 1:2 ratio of
inseparable diastereomers was obtained. This obstacle was overcome by forming the
diastereomers with the nitrile functional group still intact, providing a separable mixture. This
established synthetic route was used to synthesize and isolate rupestine C in 6 steps with an
overall yield of 2.4%. It is proposed that rupestine B can also be isolated via this route with
careful consideration of the temperature and Grignard equivalents.
The resulting methyl ketone of rupestine D and epi-rupestine D then served as the starting
material for the synthesis of rupestine K and J respectively. In order to access the alpha hydroxy
ketone of rupestine K, a silyl enol ether was formed and carried through a Rubottom oxidation.
Rupestine K was synthesized and isolated as a single diastereomer in 8 steps from picolyl
bromide 1.62 with low to excellent yields. The formation of rupestine J from epi-rupestine K
using a Wittig reaction is currently in progress.
The synthesis of rupestines L and M was studied but not accomplished. The proposed
synthetic route required a Baeyer-Villiger oxidation of rupestine D and epi-rupestine D. It was
determined that the methyl ketone was not reactive enough for oxygen insertion, and only the
pyridine N-oxide of the substrate was recovered. New synthetic routes for the synthesis of
rupestines L and M are currently being explored by other members of the Vyvyan research
group.
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7.0 Experimental
General Experimental Methods
All reactions were carried out in oven-dried glassware. Air sensitive reactions were run
under argon or nitrogen gas. Dry solvents were either freshly distilled or obtained from an
Innovative Technology Pure-Solv™ 400 Solvent Purification System. Anhydrous 1,4-dioxane was
purchased from Alfa Aesar.
Purification of compounds was accomplished via flash or radial chromatography in
hexanes/ethyl acetate solvent systems unless otherwise noted. Silica gel (40-63 m) was used in
the hand-packed flash columns and 2 mm - 4 mm silica gel rotors were used in radial
chromatography. 200 m thick silica plates from Sorbtech were used for TLC.
1

H and

13

C NMR data was acquired on a Varian MercuryPlus (300 MHz) or a Bruker

Avance III (500 MHz) spectrometers. All NMR samples were prepared in CDCl3. 1H NMR spectra
were referenced to tetramethylsilane (TMS) at 0.00 ppm and 13C NMR spectra were referenced to
CDCl3 at 77.0 unless otherwise noted. All spectra were processed using MestreNova software
where chemical shifts are in units of ppm and coupling constants are reported in Hz.
All infrared spectra were acquired on a Thermo iS10 FT-IR with a diamond ATR at 16-32
scans with a resolution of 1 cm-1. Large scale characterization was accomplished by placing the
compound directly on the ATR while small scale characterization was often done by placing a
drop of the NMR sample on the ATR and allowing the CDCl3 to evaporate.
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Preparation of (3-(allyloxy)-2-(2-cyano-hex-5-enyl)-6-methyl)pyridine
(2.6).

Notebook Entries: BJMA013, BJMA065, BJMA089
A flask was put under argon and charged with dry THF and placed over a dry ice/isopropyl
alcohol slush bath. LHMDS (1 M, 12.0 mL, 12.0 mmol) was added followed by drop-wise
addition of 5-hexenitrile (2.5) (1.30 mL, 10.2 g, 11.6 mmol) diluted in THF (1.5 mL). Pyridyl
bromide (1.62) (2.6164 g, 10.8 mmol) dissolved in THF (10 mL) was added drop-wise and the
flask was allowed to stir overnight. The reaction was quenched with sat. NH4Cl and diluted in
ether (100 mL). The layers were separated and the aqueous layer was extracted with ether and
the organic layers were combined. The organic layer was washed with brine and dried over
Na2SO4 for 1 hr. Flash chromatography (3:1 hexanes:EtOAc) gave 2.6 (2.118 g, 8.26 mmol,
77%) as a colorless oil.
FT-IR: 3056, 2965, 2926, 2867, 2238, 1642, 1581, 1257, 1125, 993, 916, 816, 732, 703 cm-1.
H NMR (300 MHz, CDCl3)  7.02 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.04 (dddd, J =
5.15, 10.43, 15.69, 17.26 Hz, 1H), 5.77 (dddd, J = 6.21, 7.02, 10.18, 13.24 Hz, 1H), 5.39 (dq, J =
1.64, 17.27 Hz, 1H), 5.30 (dq, J = 1.42, 10.53 Hz, 1H), 4.53 (dt, J = 1.57, 5.15 Hz, 2H), 3.343.19 (m, 2H), 3.06-2.94 (m, 1H), 2.5-2.1 (m, 5H), 1.85-1.6 (m, 2H) ppm.
1

C NMR (75 MHz, CDCl3)  150.5, 149.3, 145.7, 136.5, 132.6, 121.94, 121.91, 199.2, 117.7,
115.8, 68.9, 34.3, 31.01, 30.98, 29.5, 23.2 ppm.
13
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Preparation of (3-hydroxy-2-(2-cyano-hex-5-enyl)-6-methyl)pyridine
(2.7).

Notebook Entries: BJMA019, BJMA067, BJMA091
Allyl ether (2.6) (1.954 g, 7.622 mmol) was added to a flask with Pd(PPh3)4 (0.1053 g, 0.0911
mmol) and K2CO3 (3.1430 g, 22.7 mmol) and placed under argon. MeOH (40 mL) was added
and the reaction was allowed to stir at room temperature (rt). The solution was left stirring
overnight before being taken up in CH2Cl2 (50 mL) and washed with sat. NH4Cl. The layers
were separated and the aqueous layer was extracted twice with CH2Cl2 (20 mL) and all of the
organic layers were combined and dried over NaSO4. Crude product would not completely
dissolve for purification. Flash chromatography on dissolved product (2:1 hexanes:EtOAc) gave
2.7 (0.511 g, 2.36 mmol, 31%) as a white solid. Subsequent product loss resulted from flask
shattering. A second flash column was run (2:1 hexanes:EtOAc) and combined with the
previously purified product to give 2.7 (0.622 g, 2.88 mmol, 37.7%) as a white solid.
FT-IR: 2921, 2455(br), 2239, 1640, 1577, 1280, 1123, 1004, 929, 842 cm-1.
H NMR (300 MHz, CDCl3)  7.02 (dd, J = 8.2, 1H), 6.90 (dd, J = 8.2, 1H), 5.85-5.65 (m, 1H)
5.15-4.95 (m, 1H), 4.2-4.0 (m, 2H), 3.30-3.15 (m, 2H), 3.05-2.93 (m, 1H), 2.45 (s, 3H) ppm.
1

C NMR (300 MHz, CDCl3)  150.0, 147.9, 144.1, 136.4, 123.9, 123.4, 121.7, 116.1, 34.2,
31.2, 31.1, 30.0, 22.4 ppm.
13
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Preparation of (2-(2-cyano-hex-5-enyl)-6-methyl-3(((trifluoromethyl)sulfonyl)oxy))pyridine (2.3).

Notebook Entries: BJMA023, BJMA053, BJMA073, BJMA093
Phenol (2.7) (0.6235 g, 2.88 mmol) and PhNTf2 (1.0202 g, 2.85 mmol) were placed in a flask
under nitrogen and dissolved in dry CH2Cl2 (17 mL). The reaction mixture was placed over an
ice bath before subsequent addition of Et3N (0.500 mL, 0.363 g, 3.59 mmol). The reaction
progress was checked by TLC (3:1 hexanes:EtOAc) 2.5 hr later and revealed unreacted starting
material. An additional portion of Et3N (0.061 mL, 0.0443 g, 0.438 mmol) and PhNTf2 (0.1630
g, 0.4563 mmol) were added and the solution was allowed to stir overnight. TLC revealed slight
unreacted starting material so additional Et3N (0.100 mL, 0.0726 g, 0.717 mmol) and PhNTf
(0.0563 g, 0.158 mmol) were added. After 1 hr, no starting material remained so the reaction
mixture was diluted in ether and washed with sat. NH4Cl, 10% NaOH and then brine. The layers
were separated and the organic layer was dried over Na2SO4. Flash chromatography (6:1
hexanes:EtOAc) gave 2.3 (0.818 g, 2.35 mmol, 77%) as a clear yellow oil.
FT-IR: 3081, 2930, 2241, 1643, 1594, 1210, 1136, 1083, 918, 865, 830, 703 cm-1.
H NMR (300 MHz, CDCl3)  7.49 (dd, J = 8.53 Hz, 1H), 7.13 (d, J = 8.71 Hz, 1H), 5.79 (dddd,
J = 6.28, 7.05, 10.2, 13.4 Hz, 1H) 5.19-5.02 (m, 2H), 3.49-3.35 (m, 1H), 3.24 (dd, J = 15.3, 8.55
Hz, 1H), 3.05 (dd, J = 15.2, 6.41 Hz, 1H) 2.59 (s, 3H) ppm.
1

C NMR (300 MHz, CDCl3)  158.6, 148.6, 143.1, 136.1, 129.4, 129.3, 123.1, 121.2, 118.4 (q,
J = 320 Hz), 116.3, 33.9, 30.99, 30.96, 28.9, 23.9 ppm.
13
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Preparation of 2-Methyl-5-methlyene-6,7,8,9-tetrahydro-5H-5cyclohepten[b]pyridine-8-carbonitrile (2.2, table 1, entry 6).

Notebook Entries:
BJMA031, BJMA039, BJMA061, BJMA075, BJMA095, BJMA105, BJMB047
Triflate (2.3) (0.865 g, 2.483 mmol) was added to a screw cap culture tube with K2CO3 (1.7324
g, 12.53 mmol) and Pd(PPh3)4 (0.1445 g, 0.1250 mmol) and placed under nitrogen. Dry dioxane
(30 mL) was then added and the septa was quickly exchanged with a screw cap. The reaction
tube was placed on a heating mantel at 130 °C and allowed to stir overnight. The reaction was
monitored by TLC (3:1 hexanes:EtOAc) until no starting material remained (24 hr). The solution
was filtered through a fritted funnel with silica gel and rinsed (x3) with EtOAc. The filtrate was
concentrated on the rotavap and purified via radial chromatography (1:1 hexanes:EtOAc).
A white solid (0.24 g, 1.21 mmol, 49% yield, mp = 78.5-80.1 °C) was obtained.
FT-IR: 3080, 2926, 2858, 2236, 1629, 1589, 1563, 911, 839 cm-1.
H NMR (300 MHz, CDCl3):  7.41 (d, J = 7.74 Hz, 1H), 7.02 (d, J = 7.74 Hz, 1H), 5.24 (s, 1H),
5.09 (s, 1H) 3.28 (d, J = 5.88 Hz, 2H), 3.04 (qunitet, J = 5.87, 11.72 Hz, 1H) 2.73-2.41 (m, 2H)
2.52 (s, 3H), 2.18-2.12 (m, 2H) ppm.
1

C NMR (300 MHz, CDCl3):  156.89, 153.45, 147.28, 136.37, 135.25, 122.07, 121.28, 116.71,
40.79, 33.29, 32.97, 27.65, 24.04 ppm.
13

HRMS (ESI, TOF) m/z: calcd for C13H14N2Na 221.1055; found 221.1050
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Preparation of 1-(2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-yl)ethan-1-one (2.1).

Notebook Entries: BJMA049, BJMA081
Preparation of Grignard reagent (MgMeI). An oven dried flask with stir bar equipped with water
cooling reflux condenser was charged with crushed Mg turnings (0.2493 g, 10.26 mmol). The
reaction flask was put under nitrogen and methyl iodide (0.65 mL, 1.148 g, 10.44 mmol) was
added drop wise over the course of 30 minutes. The presence of unreacted Mg turnings required
additional methyl iodide (0.2 mL, 0.456 g, 3.21 mmol) Once all Mg turnings were reacted, the
flask was placed over an ice bath.
A separate oven dried flask with stir bar was charged with nitrile (2.2) and put under nitrogen.
Distilled benzene (3 mL) was transferred to the flask and the reaction was allowed to stir. The
synthesized Grignard reagent (3 mL, 3.418 M) was added to the reaction flask drop wise and
allowed to stir overnight. Reaction was quenched by adding pH=5.2 acetic acid/sodium acetate
buffer solution dropwise while reaction was kept stirring. The crude mixture was transferred to a
125-mL separatory funnel with 25 mL of ether and 25 mL of water. The aqueous layer was
extracted with ether (20 mL, x3). The organic layers were combined and washed with H2O (20
mL, x2) and brine (20 mL, x2) and dried over Na2SO4. The crude reaction mixture was purified
via radial chromatography (2 mm, EtOAc, 4.8 mL/min) to provide the product 2.1 as a yellow oil
(0.022 g, 0.102 mmol, 53% yield).
FT-IR: 3079, 2927, 2855, 1709, 1630, 1599, 1563 cm-1.
H NMR (300 MHz, CDCl3)  7.38 (d, J = 7.7 Hz, 1H), 6.96 (d, J = 7.7 Hz, 1H), 5.15 (d, J =
1.13 Hz, 1H), 5.04 (d, J = 1.6 Hz, 1H), 3.18-3.02 (m, 2H), 2.83-2.59 (m, 2H) 2.49 (s, 3H), 2.362.26 (m, 1H), 2.20 (s, 3H), 2.06-1.99 (m, 2H), 1.94-1.82 (m, 1H) ppm.
1

C NMR (300 MHz, CDCl3)  210.38, 156.4, 156.2, 148.4, 136.0, 135.2, 121.3, 115.5, 49.3,
39.7, 33.7, 31.9, 28.4, 24.1 ppm.
13

HRMS (ESI, TOF) m/z: calcd for C14H17NONa 238.1208; found 238.1215
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Preparation of 1-(2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-yl)ethan-1-one (1.69, 2.0).

Notebook Entries: BJMA063, BJMA085,
A flask containing the substrate (2.1) was charged with a stir bar, Pd/C (0.0103 g, mmol) and
methanol (1.6 mL). The flask was flushed with argon and an balloon filled with H2 was obtained.
The first H2 balloon was used to flush the reaction flask and the second balloon was left to react
overnight. After removal of the H2 balloon, the reaction flask was purged with argon. The crude
product was filtered through a celite pipette and rinsed (x3) with EtOAc. Concentration of
filtrate via rotary evaporation gave the crude product as a yellow oil of mass 0.0205 g (0.1 mmol
92%).
FT-IR: 2961, 2923, 2853, 1709, 1591, 1574, 1463 cm-1.
H NMR (300 MHz, CDCl3)  7.36 (d, J = 7.85 Hz, 1H), 7.29 (d, J = 7.72 Hz, 1H), 6.97 (d, J =
7.87 Hz, 1H), 6.91 (d, J = 7.72 Hz, 1H), 3.35-3.09 (m, 4H), 3.03-2.91 (m, 2H), 2.72-2.64 (m,
1H), 2.49 (s, 3H), 2.47 (s, 3H), 2.21, (s, 3H), 2.20 (s, 3H), 2.08-1.69 (m, 2H), 1.92-1.70 (m,
6H)1.34-1.24 (m, 7H) ppm.
1

C NMR (300 MHz, CDCl3)  211.09, 210.81, 159.18, 157.52, 154.67, 154.46, 137.89, 137.85,
132.52, 132.52 121.36, 121.21, 49.55, 49.55, 39.52, 39.52, 35.03, 35.03, 34.79, 34.79, 32.95,
32.20, 28.60, 28.48, 28.21, 23.78, 20.35, 18.93 ppm.
13
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Preparation of 2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-carbonitrile (2.8 and 2.9).

Notebook Entries: BJMB031, BJMB039, BJMB075, BJMB079, BJMB087, BJMB135,
BJMB177,
A single neck 25-mL round bottom flask equipped with a stir bar was charged
with substrate 2.2 (0.084 g, 0.42 mmol), 10 %w/w Pd/C (0.046 g, 0.432 mmol) and methanol
(6.2 mL). The reaction mixture was allowed to stir and flushed N2 (g) for 5 minutes, after which
the N2 was removed and an H2 balloon was added. The reaction flask was flushed with the first
H2 balloon. The second H2 balloon was allowed to react overnight at room temperature. The
crude reaction mixture was filtered over a 3 cm plug of Celite and rinsed with 5 mL portions
of EtOAc (x3). The filtrate was collected in a round bottom flask and concentrated via rotary
evaporation to provide a clear yellow oil in a 94% yield. The product mixture was separated via
radial chromatography (2mm, 1:3 hexanes/ethyl acetate) and two fractions were isolated.
Fraction 1 (2.8) was obtained as a clear yellow oil (0.013 g, 0.065 mmol, 15%).
FT-IR: 2961.75, 2923.2, 2854.5, 2238.1, 1591.7, 1573.2, 1463 cm-1.
H NMR (300 MHz, CDCl3):  7.38 (d, J = 7.88 Hz, 1H), 7.01 (d, J = 7.87 Hz, 1H), 3.38 (d, J =
6.45 Hz, 2H), 2.99 (ddq, J = 1.61, 6.59, 8.67 Hz, 1H), 2.73 (dddd, J = 3.53, 6.29, 6.29, 9.8 Hz,
1H), 2.49 (s, 3H), 2.28-2.17 (m, 1H) 2.13-2.05 (m, 1H), 2.00-1.91 (m, 2H), 1.34 (d, J = 7.11 Hz,
3H) ppm.
1

C NMR (300 MHz, CDCl3):  157.48 154.17, 137.43, 131.80, 121.97, 121.94, 41.04, 35.10,
33.67, 33.05, 28.79, 22.26, 17.35 ppm.
13

GCMS m/z 200.2 (M+, 52.32%)
HRMS (ESI, TOF) m/z: calcd for C13H16N2 200.1313; found 201.1392
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Fraction 2 (2.9) was obtained a white semi-solid in a (0.049 g, 0.24 mmol, 58%, mp = 77.078.8 C).
FT-IR: 2962, 2954, 2881, 2236, 1589, 1577, 1462 cm-1.
H NMR (300 MHz, CDCl3):  7.39 (d, J = 7.87 Hz, 1H), 7.01 (d, J = 7.86 Hz, 1H), 3.35 (d, J =
5 Hz, 2H), 3.07 (apparent quintet, J = 4.94 Hz, 1H), 2.94 (ddq, J = 2.32, 6.87, 9.19 Hz, 1H), 2.52
(s, 3H), 2.30-2.20 (m, 1H) 2.12-2.02 (m, 1H), 1.86-1.81 (m, 2H), 1.36 (d, J = 7.13 Hz, 3H) ppm.
1

C NMR (300 MHz, CDCl3):  155.75, 155.12, 137.56, 134.19, 121.97, 120.64, 40.36, 36.07,
32.60, 32.25, 27.83, 23.85, 19.84 ppm.
13

GCMS: m/z 200.2 (M+, 64.02%).
HRMS (ESI, TOF) m/z: calcd for C13H16N2 200.1313; found 201.1392
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Preparation of 1-((5S,8R)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)ethan-1-one (2.0).

Notebook Entries: BJMB037, BJMB043, BJMB179,
An oven dried flask equipped with a water-cooling reflux condenser and stir bar was charged
with crushed magnesium turnings (0.247 g, 10.2 mmol) and two small iodine crystals. The flask
was put under nitrogen and the solids were covered in anhydrous ether (1.5 mL). Methyl iodide
(0.63 mL, 1.43 g, 10.1 mmol) was added drop-wise over the course of 30 minutes, after which
the flask was placed over an ice bath. A separate oven dried flask containing a stir bar and the
nitrile substrate (11b, 0.010 g, 0.05 mmol) was put under nitrogen and dissolved in distilled
benzene (1.3 mL). This flask was then placed over an ice bath and allowed to stir. The entire
solution containing the Grignard reagent was added to the nitrile solution and the reaction
mixture was allowed to warm to room temperature overnight. The solution was quenched with 3
mL of pH = 5.2 acetic acid buffer and transferred to a 125-mL separatory funnel with 25 mL of
ether and 15 mL of water. The aqueous layer was extracted with 25 mL of ether (x2). The
organic layers were combined and washed with 25 mL brine (x2). The resulting organic layers
were dried over sodium sulfate. The solution was then concentrated under vacuum and the crude
mixture was purified via radial chromatography (2 mm, ethyl acetate). The purified product was
obtained as a clear/white semi-solid (0.006 g, 0.03 mmol, 55%).
FT-IR: 2960, 2925, 1707, 1591, 1574, 1463, 1354, 1160, 1035, 825 cm-1.
H NMR (300 MHz, CDCl3):  7.34 (d, J = 7.76 Hz, 1H), 6.95 (d, J = 7.76 Hz, 1H), 3.38-3.21
(m, 2H), 3.05-2.94 (m, 1H), 2.75-2.67 (m, 1H), 2.49 (s, 3H), 2.21 (s, 3H), 2.10-1.98 (m, 2H),
1.91-1.82 (m, 2H), 1.80-1.70 (m, 2H), 1.31 (d, J = 7.28 Hz, 3H) ppm.
1

C NMR (300 MHz, CDCl3):  159.3, 154.4, 136.9, 135.4, 120.8, 73.5, 47.3, 43.5, 39.1, 36.5,
33.6, 27.4, 26.4, 26.1, 23.7, 18.4 ppm.
13
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Preparation of 1-((5S,8S)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)ethan-1-one (1.18).

Notebook Entry: BJMB083, BJMB181
An oven dried flask equipped with a water-cooling reflux condenser and stir bar was charged
with crushed magnesium turnings (0.232 g, 9.5 mmol) and two small iodine crystals. The flask
was put under argon and the solids were covered in anhydrous ether (1.2 mL). Methyl iodide
(0.60 mL, 1.368 g, 9.6 mmol) was added drop-wise over the course of 20 minutes, after which
the flask was placed over an ice bath. A separate flask containing a stir bar and the nitrile
substrate (B075_F2 and B079_F2, 0.029 g, 0.145 mmol) was put under argon and dissolved in
distilled benzene (2.4 mL). This flask was then placed over an ice bath and allowed to stir. The
entire solution containing the Grignard reagent was added to the nitrile solution and the reaction
mixture was allowed to warm to room temperature overnight. The solution was quenched with 1
mL of pH = 5.2 acetic acid buffer and transferred to a 125-mL separatory funnel with 20 mL of
ether and 20 mL of water. The aqueous layer was extracted with 25 mL of ether (x3). The
organic layers were combined and washed with 25 mL brine (x2). The resulting organic layer
was dried over over sodium sulfate. The solution was then concentrated under vacuum and the
crude mixture was purified via radial chromatography (2 mm, 1:3 hexanes/ethyl acetate). The
purified product was obtained as a white crystalline solid (0.028 g, 0.129 mmol, 93%).
FTIR: 2960, 2922, 1709, 1591, 1462, 1354, 1159, 830, 813 cm-1.
H NMR (300 MHz, CDCl3):  7.37 (d, J = 8.2 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 3.22 (dd, J =
14.1, 10.0 Hz, 1H), 3.13 (dt, J = 14.1, 2.0 Hz, 1H), 3.04-2.90 (m, 1H), 2.54 (tt, J = 10.5, 3.0 Hz,
1H), 2.50 (s, 3H), 2.22 (s, 3H), 2.15-2.00 (m, 1H), 2.00-1.75 (m, 2H), 1.34 (d, J = 7.2 Hz, 3H),
1.35-1.20 (m, 1H) ppm.
1

C NMR (300 MHz, CDCl3):  211.1, 159.2, 154.5, 137.7, 132.4, 121.1, 49.6, 39.6, 35.0, 34.7,
32.9, 28.4, 23.8, 20.3 ppm.
13
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Preparation of 1-((5S,8R)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)propan-1-one (1.17)

Notebook Entry: BJMB133
An oven dried flask equipped with a water-cooling reflux condenser and stir bar was charged
with crushed magnesium turnings (0.2467 g, 10.15 mmol) and two small iodine crystals. The
flask was put under nitrogen and the solids were covered in anhydrous ether (0.5 mL). Ethyl
iodide (0.79 mL, 1.53 g, 9.8 mmol) was added drop-wise over the course of 30 minutes, after
which the flask was placed over an ice bath. A separate oven dried flask containing a stir bar and
the nitrile substrate (2.9, 0.0190 g, 0.095 mmol) was put under nitrogen and dissolved in distilled
benzene (2.5 mL). This flask was then allowed to stir. The entire solution containing the
Grignard reagent was added to the nitrile solution and the reaction mixture was brought to reflux
and allowed to react overnight. The solution was quenched with 5 mL of pH = 5.2 acetic acid
buffer and transferred to a 50-mL separatory funnel with 20 mL of ether and 15 mL of water.
The aqueous layer was extracted with 20 mL of ether (x2). The organic layers were combined
and washed with 25 mL brine (x2). The resulting organic layers were dried over sodium sulfate.
The solution was then concentrated under vacuum and the crude mixture was purified via radial
chromatography (2 mm, 1:2 hexanes:ethyl acetate). The purified product was obtained as a white
solid (0.008 g, 0.035 mmol, 36%). An additional fraction containing a 1:1 ratio of rupestine B
and rupestine C was obtained in a 53% yield.
FTIR: 2962, 2922, 1708, 1590, 1574, 1460, 142, 1375, 1348, 1280, 1164, 1110, 1026, 987, 972,
923, 825, 772, 731, and 690 cm-1.
H NMR (CDCl3, 300 MHz):  7.29 (d, J = 7.7, 1H), 6.91 (d, J = 7.7, 1H), 3.36-3.28 (m, 1H), 3.19
(dd, J = 14.0, 10.8, 1H), 3.04-2.96 (m, 1H), 2.67-2.72 (m, 1H), 2.56 (q, J = 7.3, 2H), 2.46 (s, 3H),
2.10-1.97 (m, 1H), 1.88-1.72 (m, 3H), 1.30 (d, J = 7.3, 3H), and 1.02 (t, J = 7.3, 3H) ppm.
1

C NMR (CDCl3, 75 MHz):  213.6, 157.8, 154.7, 137.8, 136.3, 121.2, 48.7, 40.0, 37.7, 34.3,
32.2, 28.3, 23.9, 18.8, and 7.8 ppm.
13
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Preparation of 2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-carbaldehyde (3.3).

Notebook Entries: BJMB023, BJMB051
An oven dried culture tube with stir bar was charged with 2-methyl-5-methylene-6,7,8,9tetrahydro-5H-cyclohepta[b]pyridine-8-carbonitrile (0.051 g, 0.257 mmol) and put under
nitrogen. Dry dichloromethane (2.5 mL) was added and the solution was allowed to stir. The
reaction flask was then cooled over a dry ice/isopropanol slush and DIBAL-H (1.0 M, 0.3 mL,
0.3 mmol) was added dropwise. The reaction was allowed to proceed for 3 hours and was
subsequently quenched with saturated ammonium chloride (4 mL) followed by pH = 5.2 acetic
acid/acetate buffer (1 mL). The reaction was allowed to warm to room temperature before being
transferred to a 125-mL separatory funnel with ether (20 mL) and saturated ammonium chloride.
(20 mL). The aqueous layer was extracted with ether (20 mL, x2). The organic layers were
combined and washed with pH = 5.2 acetic acid/acetate buffer (20 mL, x2), saturated sodium
bicarbonate (25 mL, x2), and brine (25 mL, x2). The organic layer was then dried over
magnesium sulfate and then concentrated under vacuum.
H NMR (300 MHz, CDCl3):  9.74 (s, 1H), 7.40 (d, J = 7.72 Hz, 1H), 6.98 (d, J = 7.7 Hz, 1H),
5.18 (s, 1H), 5.06 (s, 1H), 3.36 (d, J = 13.33 Hz, 1H), 3.01 (dd, J = 10.32, 14.66 Hz, 1H), 2.672.59 (m, 2H), 2.51 (s, 3H), 2.37-2.29 (m, 1H), 2.22-2.13 (m, 1H), 1.90-1.77 (m, 1H) ppm.
1

C NMR (300 MHz, CDCl3):  202.70, 156.45, 155.72, 148.22, 136.24, 135.33, 121.45, 115.86,
48.61, 37.54, 33.64, 29.47, 24.01 ppm.
13
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Preparation of 1-hydroxyheptan-2-one

Notebook Entries: BJMB067, BJMB101
A 15-mL oven dried culture tube with stir bar was charged with distilled hexanal (0.12 mL,
0.100 g, 1.0 mmol) and dry THF (0.6 mL). The culture tube was then sequentially charged with
paraformaldehyde (0.099 g, 3.3 mmol), 3-ethylbenzothizolium bromide (0.028 g, 0.11 mmol)
and triethylamine (0.04 mL, 0.029 g, 0.29 mmol). The reaction tube was flushed with argon and
them quickly capped and placed on a heat block at 60 °C. The reaction was allowed to proceed
for 4 days. On day 3, 1 mL of THF was added. The reaction was allowed to cool to room
temperature and was then transferred to a 125-mL separatory funnel with water (15 mL) and
DCM (20 mL). The aqueous layer was extracted with DCM (20 mL, x3) and the combined
organic layers were washed with brine (25 mL). The resulting organic layer was dried over
sodium sulfate and then concentrated under vacuum. GCMS analysis revealed a 25% desired
product however isolation was never accomplished.
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Preparation of 2,5-dimethyl-8-(1-((trimethylsilyl)oxy)vinyl)-6,7,8,9tetrahydro-5H-cyclohepta[b]pyridine (3.6)

A single neck oven dried flask with stir bar was charged with ketone (0.058 g, 0.267 mmol), put
under argon and dissolved in dry THF (2.0 mL). A separate oven dried flask with stir bar was put
under argon and charged with dry THF (2.0 mL) and LHMDS (0.82 mL, 0.82 mmol, 3 equiv).
Both reaction flasks were cooled to -78 °C in dry ice/isopropanol baths. The solution containing
the ketone was added dropwise to the LHMDS solution over the course of 20 minutes. The
combined solution was allowed to stir at -78 °C for 30 minutes, after which TMSCl (0.30 mL,
0.26 g, 2.4 mmol, 9.0 equiv) was added. The reaction mixture was allowed to stir for 45 minutes
at -78 °C and then for 15 minutes at 0 °C. The reaction solution was transferred to a single neck
flask and concentrated under vacuum. Hexanes (6 mL) was added and the solution was allowed
to stir for 5 minutes at room temperature. The solution was then filtered over 1 cm of celite in a
pipet and rinsed with 20 mL of hexanes. The filtrate was concentrated under vacuum and a crude
yellow liquid was obtained (0.086 g, 112%).
****Having trouble tabulating the NMR data for the crude mixture
FT-IR: 2960, 2924, 1626, 1591, 1575, 2462, 1252, 1017, 919, 846 cm-1.
H NMR (500 MHz, CDCl3):  7.35 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 6.94 (d, J = 7.8
Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 3.89 (s, 2H), 3.79 (s, 2H), 3.07-2.88 (m, 4H), 2.83-2.75 (m,
2H), 2.31 (s, 3H), 2.30 (s, 3H), 1.91-1.55 (m, 8H), 1.15-1.10 (m, 8H) ppm.
1

C NMR (500 MHz, CDCl3):  163.6, 163.5, 160.4, 158.9, 154.5, 154.1, 137.9, 137.7, 136.5,
132.0, 120.8, 120.7, 87.7, 87.6, 43.43, 43.32, 42.71, 42.71, 38.19, 36.06, 35.81, 35.06, 32.56,
30.13, 23.93, 23.88, 20.51, 18.59 ppm.
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Preparation of 1-((5S,8S)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)-2-hydroxyethan-1-one and 1-((5R,8S)-2,5dimethyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-8-yl)-2hydroxyethan-1-one

Reaction procedure at 0 °C: An oven-dried flask with stir bar was charged with silyl enol ether
3.6 (0.072 g, 0.249 mmol) and 2.0 mL of dry CH2Cl2 and allowed to stir at 0 °C. Solid mCPBA
(0.056g, 0.325, 1.3 equivalents) was dissolved in 1.0 mL of dry CH2Cl2 and added to the flask
containing the substrate dropwise over 30 minutes. The resulting solution was transferred to a
125-mL separatory funnel with 20 mL of saturated NH4Cl solution. The organic layer was
washed with saturated NH4Cl (20 mL, x2), saturated Na2S2O3 (20 mL, 2x) and saturated Na2CO3
(20 mL, 2x) before being dried over Na2SO4. The resulting solution was decanted from the
drying agent and allowed to stir with TBAF (0.072 g, 0.275 mmol) at room temperature for 1
hour to remove the TMS protecting group. The mixture was then concentrated under vacuum and
purified via flash chromatography in 20% MeOH in EtOAc. One test tube containing a white
solid was isolated and confirmed to be rupestine K (1.24) (0.002 g, 0.0086 mmol, 3.4% yield). A
yellow oil containing a 1:1 mixture of 1.24 and 3.1 was isolated (0.019 g, 0.081 mmol, 33%
yield). Further attempts were made toward the isolation of each diastereomer using radial
chromatography (12% MeOH in DCM, 2 mm plate, 6.3 mL/min) however both diastereomers
were lost during the purification.
Rupestine K:
FT-IR: 3196(br), 2956, 2917, 2872, 2849, 1716, 1592, 1577, 1460, 1415 cm-1.
H NMR (300 MHz, CDCl3):  7.40 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 7.9 Hz, 1H), 4.37 (s, 2H),
3.32 (dd, J = 11.0, 14.0 Hz, 1H), 3.11 (d, J = 14.0 Hz, 1H), 3.03-2.97 (m, 1H), 2.56 (m, 1H),
2.49 (s, 3H), 2.04-1.90 (m, 3H), 1.36 (d, J = 7.0 Hz, 3H), 1.40-1.24 (m, 3H) ppm.
1

C NMR (CDCl3, 500 MHz):  212.0, 158.5, 154.7, 137.7, 132.7, 121.4, 66.8, 45.2, 39.5, 34.8,
34.8, 33.3, 23.8, 20.3 ppm.
13

59

Preparation of 2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-yl acetate

Notebook Entries: BJMA121, BJMA139, BJMB025
A round bottom flask containing a stir bar was charged with pyridyl ketone (0.1176 g, 0.5412
mmol) and dissolved in DCM (5 mL). The reaction flask was then placed over an ice bath and
allowed to stir, after which the mCPBA (0.1670 g, 0.9677 mmol) was added. The reaction flask
was allowed to warm to room temperature overnight. Due to unreacted starting material (verified
by TLC, 1:2 hexanes/EtOAc), an additional portion of mCPBA was added (0.0188 g, 0.109
mmol). A new ice bath was placed under the reaction flask before the addition of mCPBA. The
reaction was monitored by TLC 2 hours later and starting material still remained. The next day,
TLC confirmed that all starting material was consumed. Saturated Na2S2O3 (3 mL) was added
dropwise to the reaction flask followed by Na2CO3 (25 mL). The solution was transferred to a
separtory funnel and extracted with 50 mL ether (x3). The organic layers were combined and
washed with 25 mL Na2CO3 (x2) and 50 mL brine (x2). The organic layers were combined and
dried over sodium sulfate. The crude product was concentrated via rotary evaporation and
purified by radial chromatography (2 mm plate, 20% MeOH in EtOAc). A colorless oil was
obtained in a 66% yield.
GC-MS m/z (% relative intensity, ion) 233.2 (100, M+).
FTIR revealed a C=O stretch at 1700 cm-1, indicating the presence of a ketone and not an ester.
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9.0 Supporting Information
S1. 1H NMR spectrum of nitrile 2.6

S2. 13C NMR spectrum of nitrile 2.6
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S3. 1H NMR spectrum of alcohol 2.7

S4. 13C NMR spectrum of alcohol 2.7
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S5. 1H NMR spectrum of triflate 2.3

S6. 13C NMR spectrum of triflate 2.3
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S7. 1H NMR spectrum of nitrile 2.2

S8. 13C NMR spectrum of nitrile 2.2
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S9. 1H NMR spectrum of ketone 2.1

S10. 13C NMR spectrum of ketone 2.1
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S11. 1H NMR spectrum of ketones 1.18 and 2.0

S12. 13C NMR spectrum of ketones 1.18 and 2.0
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S13. 1H NMR spectrum of nitrile 2.8

S14. 13C NMR spectrum of nitrile 2.8
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S15. 1H NMR spectrum of nitrile 2.9

S16. 13C NMR spectrum of nitrile 2.9
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S17. 1H NMR spectrum of epi-rupestine D (2.0)

S18. 13C NMR spectrum of epi-rupestine D (2.0)
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S19. 1H NMR spectrum of rupestine D (1.18)

S18. 13C NMR spectrum of rupestine D (1.18)
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S21. 1H NMR spectrum of enol ether 3.6

S22. 13C NMR spectrum of enol ether 3.6
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S23. 1H NMR spectrum of rupestine K (1.24)

S24. 13C NMR spectrum of rupestine K (1.24)
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S25. 1H NMR spectrum of aldehyde 3.3

S26. 13C NMR spectrum of aldehyde 3.3
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